An observational study in Bone Marrow Failure Disorders, VEXAS Syndrome and Hemoglobinurea, Paroxysmal, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Enrolling by invitation at 1 site in United States. Open to participants aged 2 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Bone Marrow Failure Disorders with a site in United States — 21 open to participants now, 29 under way, none of them phase 3. Bone Marrow Failure Disorders · United States.
Among the 67 studies in Bone Marrow Failure Disorders with a site in United States, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2025, is one of 10 observational ones, reaches primary completion later than 21 of the 28 other live ones, and was the 61st registered.
91 studies on the registry are indexed under Bone Marrow Failure Disorders; 29 are open to participants now.
Browse Bone Marrow Failure Disorders studies →21 of the 67 studies in Bone Marrow Failure Disorders with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages 18–25
Dren Bio · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Healthy volunteers
Nationwide Children's Hospital · Sites in United States
Ages 0–12
Suneet Agarwal · Sites in United States
Ages 1–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Bone Marrow Failure Disorders studies recruiting now, 9 (39%) set no upper age limit and 12 (52%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 37 · Phase 3 3
First in 1986; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,400 is above the median of 350 across 17 observational studies indexed under Bone Marrow Failure Disorders.
Median enrollment 23 across the 55 interventional studies, 325 across the 10 observational. Of the 32 that completed or were terminated, 15 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 67 have an industry lead sponsor. The 10 most frequent:
National Heart, Lung, and Blood Institute (NHLBI) is the lead sponsor of 1,144 studies on the registry; 71 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 51 (88%) have results posted.
National Heart, Lung, and Blood Institute (NHLBI) has 9 studies filed under Bone Marrow Failure Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Bone Marrow Failure Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01659606Boston Children's HospitalRadiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita | 2026-12 |
| NCT04644016Memorial Sloan Kettering Cancer CenterCord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | 2026-12-20 |
| NCT02356653Children's Hospital of PhiladelphiaExpanded Access Protocol Using CD3+/CD19+ Depleted PBSC | 2027-01 |
| NCT03579875Masonic Cancer Center, University of MinnesotaAlpha/Beta TCD HCT in Patients With Inherited BMF Disorders | 2027-01-01 |
| NCT04356469Johns Hopkins All Children's HospitalTCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 67 studies in Bone Marrow Failure Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
STUDY DESCRIPTION:
Bone marrow failure can result from immune mediated attack on stem cells or from inherited genetic defects such as telomere biology disorders or Fanconi anemia. Aplastic anemia (AA), a prototype of bone marrow failure syndromes (BMFS), can be acquired or inherited. Acquired BMFS have common immune mediated pathophysiology, and include AA, lower risk myelodysplastic syndrome (MDS, particularly hypoMDS), VEXAS, large granular lymphocytosis (LGL), paroxysmal nocturnal hemoglobinuria (PNH), pure red cell aplasia (PRCA), or cytopenia of undetermined origin. Clonality is frequent in patients with BMFS. Patients with acquired AA are known to have somatic mutations in phosphatidylinositol glycan class A (PIGA), BCL6 corepressor (BCOR) and HLA genes, which are all related to the immune mediated pathophysiology and good predictors of treatment and overall outcomes. Others such as ASXL1, RUNX1, and splicing factor mutations and/or chromosome 7 aneuploidy are associated with secondary myeloid neoplasms in these patients. Somatic mutations in STAT, DNMT3A and TET2 are prevalent in many other BMFS, such as LGL and VEXAS. Except for acquired AA, the clonal dynamics and trajectories, and cooccurrence of these aberrations in other BMFS are poorly understood. How these clonal events interact with epigenetic and proteomic changes are also unknown. In addition, the role of novel genetic defects in marrow failure is poorly characterized, such as mutations associated with inborn errors of immunity or complement pathways. Our aim is to elucidate this further using multi-omics, bulk/single cell DNA and RNA techniques as well as understand the epigenetics using ATAC-seq, and proteomics. The translation work will be correlated with clinical outcomes and laboratory parameters of patients with the particular BMFS cohort being investigated.
OBJECTIVES:
Primary Objective: To characterize the molecular aberrations in BMFS and to understand how clonality, epigenetics, and proteomics contribute to hematopoiesis over the course of disease using high resolution multi-omics characterization of hematopoietic stem and progenitor cells (HSPC), immune cells and other cellular composition in peripheral blood and bone marrow samples.
Secondary Objectives:
STUDY DESCRIPTION:
Bone marrow failure can result from immune mediated attack on stem cells or from inherited genetic defects such as telomere biology disorders or Fanconi anemia. Aplastic anemia (AA), a prototype of bone marrow failure syndromes (BMFS), can be acquired or inherited. Acquired BMFS have common immune mediated pathophysiology, and include AA, lower risk myelodysplastic syndrome (MDS, particularly hypoMDS), VEXAS, large granular lymphocytosis (LGL), paroxysmal nocturnal hemoglobinuria (PNH), pure red cell aplasia (PRCA), or cytopenia of undetermined origin. Clonality is frequent in patients with BMFS. Patients with acquired AA are known to have somatic mutations in phosphatidylinositol glycan class A (PIGA), BCL6 corepressor (BCOR) and HLA genes, which are all related to the immune mediated pathophysiology and good predictors of treatment and overall outcomes. Others such as ASXL1, RUNX1, and splicing factor mutations and/or chromosome 7 aneuploidy are associated with secondary myeloid neoplasms in these patients. Somatic mutations in STAT, DNMT3A and TET2 are prevalent in many other BMFS, such as LGL and VEXAS. Except for acquired AA, the clonal dynamics and trajectories, and cooccurrence of these aberrations in other BMFS are poorly understood. How these clonal events interact with epigenetic and proteomic changes are also unknown. In addition, the role of novel genetic defects in marrow failure is poorly characterized, such as mutations associated with inborn errors of immunity or complement pathways. Our aim is to elucidate this further using multi-omics, bulk/single cell DNA and RNA techniques as well as understand the epigenetics using ATAC-seq, and proteomics. The translation work will be correlated with clinical outcomes and laboratory parameters of patients with the particular BMFS cohort being investigated.
OBJECTIVES:
Primary Objective: To characterize the molecular aberrations in BMFS and to understand how clonality, epigenetics, and proteomics contribute to hematopoiesis over the course of disease using high resolution multi-omics characterization of hematopoietic stem and progenitor cells (HSPC), immune cells and other cellular composition in peripheral blood and bone marrow samples.
Secondary Objectives:
This study will utilize biospecimens and data with identifiers from up to 1,400 research participants with BMFS, aged 2 years and older, alongside age matched healthy volunteers aged 8 years and older.
Biospecimens and data from age matched healthy volunteers (age 8 and up) will be used from the following protocol:- 07H0113 Procurement and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples from Healthy Volunteers to Support Clinical and Translational Research Projects in the NHLBI.
Biospecimens and data from children and adults with BMFS who participated in the following studies will be used:- 04H0012 "Collection of Tissue Specimens from Patients with Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members"Clinical and research data from children and adults with BMFS who participated in the following studies will be used:- 06H0034 "Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia"- 12H0150 "Eltrombopag with Standard Immunosuppression for Severe Aplastic Anemia"- 20H0033 "Early Initiation of Oral Therapy with Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)"- 09H0154 "A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag, in Refractory Aplastic Anemia Patients"
Detection of molecular aberrations in marrow failure
To characterize the molecular aberrations in marrow failure and to understand how clonality, epigenetics, and proteomics contribute to hematopoiesis over the course of disease using high resolution multi-omics characterization of HSPC, immune cells and other cellular composition in peripheral blood and bone marrow samples.
Time frame: baseline
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Jul 2030, 58 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bone Marrow Failure Disorders →
National Heart, Lung, and Blood Institute (NHLBI) →